Business Wire

OH-PROCTER-&-GAMBLE

11.1.2021 11:02:32 CET | Business Wire | Press release

Share
P&G Commits to Enable 2 Billion People to Adopt Healthy Oral Care Habits by 2030

Procter & Gamble (P&G) Oral Care seeks to advance healthy oral care habits to transform people’s health while reducing impact on the planet through its new sustainability commitments. The platform, “Healthy Smiles. Healthy Lives. Healthy Planet.”, guides its oral care brands, including Oral-B and Crest, to help unlock the lifechanging power of healthy oral care habits for all.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005056/en/

The World Health Organization estimates oral diseases affect 3.58 billion people, with cavities being the most prevalent issue. Both Oral-B and Crest are working to educate and enable 2 billion people to adopt healthy oral care habits by 2030, reducing their environmental footprint and enabling responsible consumption along the way.

“We are on a mission to help more people around the world understand the connection of their oral care routine to their overall health and how small changes can make a big impact,” said Alexandra Vegas, Senior Vice President Global Oral Care, P&G. “As we encourage everyone to brush twice daily for two minutes, we’ll continue to introduce products that make people want to build those healthy habits.”

Oral-B and Crest will focus their efforts on education and advocacy; enabling access to dental products and services; and innovation that makes the adoption of healthy habits enjoyable. Oral-B’s free Disney Magic Timer app, for example, is making 90% of kids brush for longer, establishing healthy brushing habits early on in childhood.

Healthy Habits for People

To drive healthy habits for people, Oral-B and Crest will improve access to oral care solutions and education to establish better oral health habits and continue to provide safe products with transparency.

During the COVID-19 pandemic, when people couldn’t visit their dentist, the brands helped protect oral health through educational articles, videos and livestreaming sessions. In the U.S., they have donated millions in product and dental care through their partnerships with Feeding America, Dental Lifeline Network and America’s Tooth Fairy. Oral-B and Crest will continue to partner with dental professionals, retailers and consumers to make progress.

Healthy Habits for the Planet

To drive healthy habits for the planet, Oral-B and Crest will encourage and enable responsible consumption by making their packaging 100% recyclable, starting with the transition to recyclable toothpaste tubes in Europe, the U.S. and Canada by 2025.

P&G Oral Care will also reduce its environmental footprint and strive for circular solutions while working with suppliers to secure transparent and responsible sourcing. Specific goals include reducing greenhouse gas emissions in operations and improving water efficiency by 35% in P&G sites by 2030.

Today P&G Oral Care factories send zero manufacturing waste to landfill globally, and all U.S. and European sites purchase 100% renewable electricity. The company has improved energy efficiency across its global Oral Care production sites by nearly 20% since 2010.

These goals are rooted in P&G's Ambition 2030 Sustainability Program, as well as three United Nations’ Sustainable Development Goals: Good Health and Wellbeing, Responsible Consumption and Production, and Reduced Inequality.

“We take a holistic approach in the way we design our oral health innovation, considering both the health of people and our planet,” said Lisa Ernst, Senior Vice President Oral Care R&D, P&G. “For example, our Oral-B electric toothbrushes help people brush better for longer and reduce oral care issues such as gum inflammation. For people who prefer to use manual toothbrushes, Oral-B Clic features replaceable toothbrush heads that reduce plastic waste by 60%.”

Visit the Oral-B website for more details on “Healthy Smiles. Healthy Lives. Healthy Planet.”

About P&G:

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com  for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release

Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp

Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o

Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release

Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio

Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building2.9.2026 13:13:00 CEST | Press release

Orascom and Muriya press ahead across Hawana Salalah, Jebel Sifah and the US$90M+ As Sodah Island, signalling long-term conviction in Oman’s future, in step with Vision 2040. Across Oman, Orascom Development and its Sultanate platform, Muriya, are moving forward. While parts of the region grow cautious, Muriya has paused nothing, building and delivering across all three destinations: Hawana Salalah, Jebel Sifah and As Sodah Island. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902781576/en/ Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building (Photo: AETOSWire) The same steadiness runs through everything Samih Sawiris and Orascom have built, from El Gouna to Andermatt to Mamula Island: identifying extraordinary places and developing them for the long term. “Oman has everything we look for as a long-term developer: stability, natural beauty, and a clear direction for its future. Our continued investment

Aukera Closes €460 Million Structured Credit Facility Led by EIG to Support European Energy Infrastructure Portfolio2.9.2026 13:00:00 CEST | Press release

Aukera, the pan-European battery storage and renewable energy platform backed by AtlasInvest, Reggeborgh and SFPIM (Belgium's sovereign wealth fund), announced the closing of its €460 million structured credit facility, for which EIG, a leading institutional investor in the global energy and infrastructure sectors, served as the lead investor. With the financing in place, Aukera moves into its next phase of growth, combining capital, expertise and delivery capability to build a significant European energy infrastructure platform that develops, finances, constructs and operates assets at scale. The original facility included an initial €200 million commitment and an accordion feature of up to €250 million. The amended facility converts that accordion into a firmly committed €260 million Series 2 tranche, increasing total committed capital to €460 million. The additional capital will support the continued advancement of Aukera's portfolio of renewable energy generation, battery storage a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye